Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00824434
Registration number
NCT00824434
Ethics application status
Date submitted
15/01/2009
Date registered
16/01/2009
Date last updated
30/08/2012
Titles & IDs
Public title
A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)
Query!
Scientific title
A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)
Query!
Secondary ID [1]
0
0
S2051
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PLATINUM QCA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Atherosclerosis
0
0
Query!
Coronary Artery Disease
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - PROMUS Element™
Experimental: Experimental Stent -
Treatment: Devices: PROMUS Element™
Drug eluting coronary stent system
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Cardiac Events (Composite)
Query!
Assessment method [1]
0
0
Percentage of patients who had a myocardial infarction, cardiac death, target lesion revascularization, or stent thrombosis (defined as definite or probable per the Academic Research Consortium \[ARC\] definitions); see below for definitions of individual components.
Query!
Timepoint [1]
0
0
30 days
Query!
Secondary outcome [1]
0
0
In-stent Late Loss
Query!
Assessment method [1]
0
0
In-stent late loss by quantitative coronary angiography in workhorse target lesions (visual reference vessel diameter \[RVD\] =2.5 mm and =4.25 mm and visual lesion length =24 mm)
Query!
Timepoint [1]
0
0
9 months
Query!
Secondary outcome [2]
0
0
Occurance of Post-procedure Incomplete Stent Apposition
Query!
Assessment method [2]
0
0
Percentage of participants who experience incomplete stent apposition as determined immediately post-procedure by intravascular ultrasound
Query!
Timepoint [2]
0
0
Post-procedure
Query!
Secondary outcome [3]
0
0
Myocardial Infarction (MI)
Query!
Assessment method [3]
0
0
New Q-waves in =2 leads lasting =0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin \>upper limit of normal(ULN); if no new Q-waves total CK levels \>3×ULN (peri-percutaneous coronary intervention \[PCI\]) or \>2×ULN (spontaneous) with elevated CK-MB or troponin \>3×ULN (peri-PCI) or \>2×ULN (spontaneous) plus =one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin \>5×ULN
Query!
Timepoint [3]
0
0
12 months
Query!
Secondary outcome [4]
0
0
All-cause Mortality
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
12 months
Query!
Secondary outcome [5]
0
0
Target Lesion Revascularization (TLR)
Query!
Assessment method [5]
0
0
Target lesion revascularization (TLR) is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Query!
Timepoint [5]
0
0
30 Days
Query!
Secondary outcome [6]
0
0
Target Lesion Revascularization (TLR)
Query!
Assessment method [6]
0
0
Target lesion revascularization (TLR) is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Query!
Timepoint [6]
0
0
12 Months
Query!
Secondary outcome [7]
0
0
Target Vessel Revascularization (TVR)
Query!
Assessment method [7]
0
0
Target vessel revascularization (TVR) is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Query!
Timepoint [7]
0
0
30 Days
Query!
Secondary outcome [8]
0
0
Target Vessel Revascularization (TVR)
Query!
Assessment method [8]
0
0
Target vessel revascularization (TVR) is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Query!
Timepoint [8]
0
0
12 months
Query!
Secondary outcome [9]
0
0
Target Lesion Failure (TLF)
Query!
Assessment method [9]
0
0
Target lesion failure (TLF) is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Query!
Timepoint [9]
0
0
12 months
Query!
Secondary outcome [10]
0
0
Target Vessel Failure (TVF)
Query!
Assessment method [10]
0
0
Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Query!
Timepoint [10]
0
0
12 months
Query!
Secondary outcome [11]
0
0
Definite + Probable Stent Thrombosis Based on Academic Research Consortium (ARC) Definition
Query!
Assessment method [11]
0
0
DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Query!
Timepoint [11]
0
0
24 hours
Query!
Secondary outcome [12]
0
0
Definite + Probable Stent Thrombosis Based on Academic Research Consortium (ARC) Definition
Query!
Assessment method [12]
0
0
DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Query!
Timepoint [12]
0
0
>24 hr-30 days
Query!
Secondary outcome [13]
0
0
Definite + Probable Stent Thrombosis Based on Academic Research Consortium (ARC) Definition
Query!
Assessment method [13]
0
0
DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Query!
Timepoint [13]
0
0
>30 days-1 year
Query!
Secondary outcome [14]
0
0
Clinical Procedural Success
Query!
Assessment method [14]
0
0
Mean lesion diameter stenosis \< 30% with TIMI 3 flow without the occurrence of in-hospital cardiac death, MI, or TVR
Query!
Timepoint [14]
0
0
Duration of hospital stay (usually 1-2 days)
Query!
Secondary outcome [15]
0
0
Technical Success
Query!
Assessment method [15]
0
0
Successful delivery and deployment of the study stent to the target lesion, without balloon rupture or embolization, summarized per stent.
Query!
Timepoint [15]
0
0
Acute-At time of index procedure
Query!
Eligibility
Key inclusion criteria
* Patient (or legal guardian) understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed
* Patient is eligible for percutaneous coronary intervention (PCI)
* Patient has documented stable angina pectoris (Canadian Cardiovascular Society [CCS] Classification 1, 2, 3, or 4) or documented silent ischemia; or unstable angina pectoris (Braunwald Class IB-C, IIB-C, or IIIB-C)
* Patient is an acceptable candidate for coronary artery bypass grafting (CABG)
* Patient has a left ventricular ejection fraction (LVEF) >=30% as measured within 30 days prior to enrollment
* Patient is willing to comply with all specified follow-up evaluations
Angiographic
* Target lesion must be a de novo lesion located in a native coronary artery with visually estimated diameter of >=2.25 mm and <=4.25 mm
* Target lesion length must measure (by visual estimate) <=34 mm
* Target lesion must be in a major coronary artery or branch with visually estimated stenosis >=50% and <100% with Thrombolysis in Myocardial Infarction (TIMI) flow >1.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute myocardial infarction (MI)
* Patient has had a known diagnosis of recent MI (within 30 days prior to the index procedure) and has elevated enzymes at the time of the index procedure as follows.
* Patients are excluded if any of the following criteria are met at the time of the index procedure
* If creatine kinase, MB band (CK-MB) >2× upper limit of normal (ULN), the patient is excluded regardless of the creatine kinase (CK) Total.
* If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is >2× ULN.
* If CK Total/CK-MB are not used and Troponin is, the patients are excluded if the following criterion is met at the time of the index procedure.
* Troponin >1× ULN with at least one of the following.
* Patient has ischemic symptoms and electrocardiogram (ECG) changes indicative of ongoing ischemia (e.g., >1mm ST segment elevation or depression in consecutive leads or new left bundle branch block [LBBB]);
* Development of pathological Q-waves in the ECG
* Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Note: For patients who have had a recent MI, CK Total/CK-MB (or Troponin if CK Total/CK-MB are not used) must be documented prior to enrolling the patient
* Patient has received an organ transplant or is on a waiting list for an organ
* transplant
* Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure
* Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)
* Patient is receiving chronic (>=72 hours) anticoagulation therapy (eg, heparin, coumadin) for indications other than acute coronary syndrome
* Patient has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3
* Patient has a white blood cell (WBC) count <3,000 cells/mm3
* Patient has documented or suspected liver disease, including laboratory evidence of hepatitis
* Patient is on dialysis or has known renal insufficiency (i.e., estimated creatinine clearance <50 mL/min by the Cockcroft Gault formula, ie [(140-age)*lean body weight (in kg)]/[plasma creatinine (mg/dL)*72])
* Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
* Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months, or has any permanent neurologic defect that may cause non-compliance with the protocol
* Target vessel or side branch has been treated with any type of percutaneous coronary intervention (PCI; eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to the index procedure
* Target vessel has been treated within 10 mm proximal or distal to the target lesion (by visual estimate) with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) at any time prior to the index procedure
* Non-target vessel or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to the index procedure
* Planned or actual target vessel treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement
* Planned percutaneous coronary intervention or coronary artery bypass grafting after the index procedure
* Patient previously treated at any time with coronary intravascular brachytherapy
* Patient has a known allergy to the study stent system or protocol-required concomitant medications (e.g., stainless steel, platinum, cobalt, chromium, nickel, tungsten, acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot be adequately premedicated
* Patient has active peptic ulcer or active gastrointestinal (GI) bleeding
* Patient has one of the following:
* Other serious medical illness (eg, cancer, congestive heart failure) that may reduce life expectancy to less than 24 months
* Current problems with substance abuse (eg, alcohol, cocaine, heroin, etc.)
* Planned procedure that may cause non-compliance with the protocol or confound data interpretation
* Patient is participating in another investigational drug or device clinical trial that has not reached its primary endpoint
* Patient intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure
* Known intention to procreate within 12 months after the index procedure
* Female with positive pregnancy test within 7 days prior to the index procedure (a pregnancy test must be performed in women of child-bearing potential prior to enrollment), or lactating
* Patient has more than 1 target lesion or more than 1 target lesion and 1 non-target lesion, identified during screening for intervention
Angiographic
* Target lesion meets any of the following criteria:
* Aorto-ostial location (i.e., lesion located within 5 mm of the ostium)
* Left main location
* Located within 5 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCX) coronary artery
* Located within a saphenous vein graft or an arterial graft
* Can only be accessed via a saphenous vein graft or an arterial graft
* Involves a side branch >=2.0 mm in diameter
* Involves a clinically significant side branch <2.0 mm in diameter that has a clinically significant stenosis at the ostium
* TIMI flow 0 (total occlusion) or TIMI flow 1 prior to wire crossing
* Excessive tortuosity proximal to or within the lesion
* Extreme angulation proximal to or within the lesion
* Target lesion and/or target vessel proximal to the target lesion is moderately to severely calcified
* Restenotic from previous intervention
* Thrombus, or possible thrombus, present in the target vessel
* Patient has an additional clinically significant lesion(s) in the target vessel for which an intervention within 12 months after the index procedure is likely to be required
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
100
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
St. Vincent's Hospital - Sydney - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Royal North Shore Hospital - St Leonards
Query!
Recruitment hospital [3]
0
0
Monash Medical Centre - Clayton
Query!
Recruitment hospital [4]
0
0
St. Vincent Hospital (Melbourne) - Fitzroy
Query!
Recruitment hospital [5]
0
0
Fremantle Hospital - Fremantle
Query!
Recruitment hospital [6]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [7]
0
0
The Prince Charles Hospital - Brisbane
Query!
Recruitment hospital [8]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [9]
0
0
Sir Charles Gairdner Hospital - Perth
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [5]
0
0
6160 - Fremantle
Query!
Recruitment postcode(s) [6]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [7]
0
0
4032 - Brisbane
Query!
Recruitment postcode(s) [8]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [9]
0
0
6009 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
Malaysia
Query!
State/province [1]
0
0
Kuala Lumpur
Query!
Country [2]
0
0
New Zealand
Query!
State/province [2]
0
0
Auckland
Query!
Country [3]
0
0
New Zealand
Query!
State/province [3]
0
0
Christchurch
Query!
Country [4]
0
0
New Zealand
Query!
State/province [4]
0
0
Dunedin
Query!
Country [5]
0
0
New Zealand
Query!
State/province [5]
0
0
Wellington
Query!
Country [6]
0
0
Singapore
Query!
State/province [6]
0
0
Singapore
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boston Scientific Corporation
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Compile acute (30-day) clinical outcomes data and 9-month angiographic and intravascular ultrasound (IVUS) data for the PROMUS Element™ Everolimus- Eluting Coronary Stent System in the treatment of patients with a single de novo atherosclerotic lesion
Query!
Trial website
https://clinicaltrials.gov/study/NCT00824434
Query!
Trial related presentations / publications
Meredith IT, Whitbourn R, Scott D, El-Jack S, Zambahari R, Stone GW, Teirstein PS, Starzyk RM, Allocco DJ, Dawkins KD. PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses. EuroIntervention. 2011 May;7(1):84-90. doi: 10.4244/EIJV7I1A15.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Ian T. Meredith, MBBS
Query!
Address
0
0
Monash Medical Centre
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Meredith IT, Whitbourn R, Scott D, El-Jack S, Zamb...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT00824434
Download to PDF